Become A Member

  1. Home
  2. 2022 (MAY-JUNE)
Article Image
Monica Kamble1 , Archana Gawade


Human Brain is a very delicate organ and it acts as vital controlling unit of body and hence it is strictly protected by nature to shield regular brain function. The Blood Brain Barrier (BBB) is one of the key barriers that prevents dangerous chemicals and medications from entering the brain. While the BBB is a thick brain barrier that prevents medicine from reaching the CNS, making it difficult to treat a variety of brain illnesses such as Alzheimer's, Parkinson's, dementia, mood disorders, neuronal-AIDS, and CNS tumors/cancers. As a result, fresh methods to the treatment of CNS brain illness are required. Novel techniques, such as magnetic drug-targeting and drug carrier systems, will effectively target the brain. The total incidence rate for CNS disease has shown that over 1.5 billion individuals suffer from central nervous system illnesses. The existence of the Blood-Brain Barrier, which has a propensity to hinder medication distribution and is a significant hindrance to the development of CNS therapies, is the most worrisome truth regarding drug delivery to the CNS. Many medications that are hydrophilic in nature, such as neuropeptides, may be able to cross through the blood brain barrier with ease. The major considerations for CNS medication development are the net quantity of administered medicine (medicinal agent) and its capacity to acquire access to the relevant target locations. Many novel developing techniques, such as biomaterials and colloidal nanoparticles systems, have been created to transport medications into the CNS by crossing the Blood-Brain Barrier (antibodies, liposomes or nanoparticles).

KEYWORDS: Blood-Brain barrier, CNS disorders, Drug delivery to brain, Nanotechnology, Colloidal drug carriers.